Country
United Kingdom
AstraZeneca Plc is to acquire the US specialty pharmaceutical company Alexion Pharmaceuticals Inc for $39 billion – at once giving it five marketed drugs and more than 20 development programmes for rare diseases and immunology.
Full text available to subscribers only. Click here for information on subscribing to MedNous.